3 months ago
LLY
AnalystsSrikripa DevarakondaSrikripa Devarakonda's Stock Forecasts
AnalystsSrikripa Devarakonda
Sectors:
Industries:
Analyst Ranking
Bottom 11%
#4386 out of 4866 analysts
Average Return
-7.55%
Win Rate
27%16 out of 59
Risk vs Reward
Poor
Good
Srikripa Devarakonda's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Verastem IncVSTM | +182.73% | $2.49 | $7.04 | 2024-08-13 - 2025-04-22 | Strong Buy |
Verastem IncVSTM | +169.73% | $2.61 | $7.04 | 2024-07-08 - 2025-04-22 | Strong Buy |
Edgewise Therapeutics IncEWTX | +131.48% | $7.56 | $17.50 | 2023-06-28 - 2024-06-27 | Strong Buy |
Scholar Rock Holding CorpSRRK | +113.66% | $15.23 | $32.54 | 2024-04-03 - 2025-04-02 | Strong Buy |
Scholar Rock Holding CorpSRRK | +111.18% | $16.01 | $33.81 | 2024-03-25 - 2025-03-24 | Strong Buy |
Srikripa Devarakonda Analyst Color
Get additional color on Srikripa Devarakonda's coverage of popular stocks
4 months ago
PFE
5 months ago
EWTX
5 months ago
SRRK
6 months ago
LLY
10 months ago
LLY
a year ago
LLY
a year ago
KYMR
Srikripa Devarakonda's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Keros Therapeutics IncKROS | 5 | Strong Buy | $25.00 | +79.99% | Maintains | 14 days ago |
Incyte CorpINCY | 9 | Hold | $72.00 | +25.48% | Maintains | a month ago |
Protagonist Therapeutics IncPTGX | 2 | Strong Buy | $76.00 | +65.76% | Maintains | a month ago |
Biogen IncBIIB | 3 | Strong Buy | $210.00 | +76.63% | Maintains | 2 months ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $1,038.00 | +25.43% | Maintains | 3 months ago |
Abbvie IncABBV | 3 | Strong Buy | $217.00 | +24.87% | Maintains | 3 months ago |
Regeneron Pharmaceuticals IncREGN | 5 | Strong Buy | $1,004.00 | +71.48% | Maintains | 3 months ago |
Pfizer IncPFE | 1 | Strong Buy | $32.00 | +42.03% | Maintains | 4 months ago |
Edgewise Therapeutics IncEWTX | 6 | Strong Buy | $50.00 | +269.55% | Maintains | 5 months ago |
Scholar Rock Holding CorpSRRK | 4 | Strong Buy | $45.00 | +42.23% | Maintains | 5 months ago |
Kymera Therapeutics IncKYMR | 3 | Strong Buy | $53.00 | +84.03% | Reiterates | 6 months ago |
Biomea Fusion IncBMEA | 1 | Strong Buy | $54.00 | +2,669.23% | Upgrades | 7 months ago |
Verastem IncVSTM | 7 | Strong Buy | $15.00 | +113.07% | Maintains | 8 months ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $36.00 | +214.14% | Initiates Coverage On | 9 months ago |
Cytokinetics IncCYTK | 4 | Strong Buy | $70.00 | +85.14% | Maintains | a year ago |
Affimed NvAFMD | 2 | Strong Buy | $60.00 | N/A | Maintains | 2 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $38.00 | N/A | Downgrades | 2 years ago |
Constellation Pharmaceuticals IncCNST | 2 | Hold | $34.00 | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.